Putting Patients In Charge Of Drug Development. Like CEO In Charge
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA, PhRMA and BIO leadership could look considerably different under a modest proposal from National Health Council's Marc Boutin.
You may also be interested in...
FDA Succession Planning Targeted In House Legislation
Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in 21st Century Cures bill would mandate a similar process always be followed.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.
Pink Sheet Podcast: Mifepristone And Misinformation At SCOTUS, Understanding US FDA’s ODAC
Pink Sheet reporters and editor discuss the upcoming US Supreme Court arguments on mifepristone access, the SCOTUS reaction to the fight against misinformation, and the FDA’s Oncologic Drugs Advisory Committee going against three negative product reviews.